Personalized Medicine Universe最新文献

英文中文

Safety and efficacy of a dietary supplement containing functional food ingredients for erectile dysfunction 含有功能性食品成分的膳食补充剂治疗勃起功能障碍的安全性和有效性

Personalized Medicine Universe

Pub Date : 2014-07-01 DOI: 10.1016/j.pmu.2014.03.002

Seika Kamohara M.D., Ph.D , Masakatsu Kageyama , Satoshi Sunayama M.D., Ph.D , Kozo Denpo Ph.D

Purpose

Functional food ingredients are widely used for erectile dysfunction. We conducted 2 clinical studies to evaluate the safety and efficacy of a commercialized dietary supplement containing Panax ginseng C.A. Meyer extract, Lepidium meyenii root extract, yeast extract, egg white peptide, Mucuna pruriens extract, black ginger extract, polyphenol, l-arginine, l-carnitine, coenzyme Q₁₀, vitamin E, black pepper extract, and zinc.

Methods

In the first study, after providing informed consent, 15 healthy men (mean age, 35.3 ± 1.9 years) participated. A dietary supplement, EDiSON was administered for 8 weeks. Adverse events were recorded daily. In the second study, 14 men diagnosed with mild-to-moderate erectile dysfunction participated in an 8-week randomized, double-blind, placebo-controlled study. They were assigned to the dietary supplement group (n = 8) or the placebo group (n = 6). The primary outcome was the quality of life, as assessed by the International Index of Erectile Function-5 (IIEF-5) questionnaire.

Results

All patients completed the studies. In the first study, the intake of the dietary supplement was not associated with any adverse events. In the second study, the intake of the supplement was associated with significant improvement of the IIEF-5 score at 4 weeks and at 8 weeks of the trial, compared to the baseline.

Conclusion

Our initial findings support the safety of the EDiSON dietary supplement. The results from the randomized, double blind, placebo-controlled trial support the use of the EDiSON dietary supplement for the treatment of mild-to-moderate erectile dysfunction. This study was registered at http://www.umin.ac.jp, as UMIN000009405.

目的功能性食品成分被广泛用于治疗勃起功能障碍。我们进行了2项临床研究，以评估一种商业化膳食补充剂的安全性和有效性，该膳食补充剂含有人参C.A. Meyer提取物、Lepidium meyenii根提取物、酵母提取物、蛋清肽、Mucuna pruriens提取物、黑姜提取物、多酚、l-精氨酸、l-肉碱、辅酶Q10、维生素E、黑胡椒提取物和锌。方法在第一项研究中，在提供知情同意后，15名健康男性(平均年龄35.3±1.9岁)参与研究。作为一种膳食补充剂，爱迪生被给予8周。每天记录不良事件。在第二项研究中，14名被诊断为轻度至中度勃起功能障碍的男性参加了一项为期8周的随机、双盲、安慰剂对照研究。他们被分配到膳食补充剂组(n = 8)或安慰剂组(n = 6)。主要结果是生活质量，由国际勃起功能指数-5 (IIEF-5)问卷评估。结果所有患者均完成研究。在第一项研究中，摄入膳食补充剂与任何不良事件无关。在第二项研究中，与基线相比，在试验的第4周和第8周，补充剂的摄入与IIEF-5评分的显著改善有关。我们的初步研究结果支持EDiSON膳食补充剂的安全性。这项随机、双盲、安慰剂对照试验的结果支持使用EDiSON膳食补充剂治疗轻度至中度勃起功能障碍。本研究注册号为http://www.umin.ac.jp，编号为UMIN000009405。

{"title":"Safety and efficacy of a dietary supplement containing functional food ingredients for erectile dysfunction","authors":"Seika Kamohara M.D., Ph.D , Masakatsu Kageyama , Satoshi Sunayama M.D., Ph.D , Kozo Denpo Ph.D","doi":"10.1016/j.pmu.2014.03.002","DOIUrl":"https://doi.org/10.1016/j.pmu.2014.03.002","url":null,"abstract":"<div><h3>Purpose</h3><p><span>Functional food<span> ingredients are widely used for erectile dysfunction. We conducted 2 clinical studies to evaluate the safety and efficacy of a commercialized dietary supplement containing </span></span><span><em>Panax </em><em>ginseng</em></span> C.A. Meyer extract, <em>Lepidium meyenii</em> root extract, yeast extract, egg white peptide, <em>Mucuna pruriens</em><span> extract, black ginger extract, polyphenol, </span><span>l</span>-arginine, <span>l</span>-carnitine, coenzyme Q<sub>10</sub><span>, vitamin E, black pepper extract, and zinc.</span></p></div><div><h3>Methods</h3><p><span>In the first study, after providing informed consent, 15 healthy men (mean age, 35.3 ± 1.9 years) participated. A dietary supplement, EDiSON was administered for 8 weeks. Adverse events were recorded daily. In the second study, 14 men diagnosed with mild-to-moderate erectile dysfunction participated in an 8-week randomized, double-blind, placebo-controlled study. They were assigned to the dietary supplement group (</span><em>n</em> = 8) or the placebo group (<em>n</em><span> = 6). The primary outcome was the quality of life, as assessed by the International Index of Erectile Function-5 (IIEF-5) questionnaire.</span></p></div><div><h3>Results</h3><p>All patients completed the studies. In the first study, the intake of the dietary supplement was not associated with any adverse events. In the second study, the intake of the supplement was associated with significant improvement of the IIEF-5 score at 4 weeks and at 8 weeks of the trial, compared to the baseline.</p></div><div><h3>Conclusion</h3><p><span>Our initial findings support the safety of the EDiSON dietary supplement. The results from the randomized, double blind, placebo-controlled trial support the use of the EDiSON dietary supplement for the treatment of mild-to-moderate erectile dysfunction. This study was registered at </span><span>http://www.umin.ac.jp</span><svg><path></path></svg>, as UMIN000009405.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"3 ","pages":"Pages 38-41"},"PeriodicalIF":0.0,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2014.03.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91774491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Personalized medicine-based strategy for prostate cancer 针对前列腺癌的个性化医疗策略

Personalized Medicine Universe

Pub Date : 2014-07-01 DOI: 10.1016/J.PMU.2014.03.007

A. Gotoh

引用次数: 4

Role of mitochondrial DNA changes in prostate cancer progression 线粒体DNA变化在前列腺癌进展中的作用

Personalized Medicine Universe

Pub Date : 2014-07-01 DOI: 10.1016/j.pmu.2014.03.005

Masahiro Higuchi Ph.D., Ara Kim, Cody C. Cook, Sara Prior, Akinobu Gotoh

引用次数: 0

Marked improvement of neurocognitive impairment after treatment with compounds from Hericium erinaceum: A case study of recurrent depressive disorder 用猴头草化合物治疗后神经认知障碍的显著改善:复发性抑郁症的一个案例研究

Personalized Medicine Universe

Pub Date : 2014-07-01 DOI: 10.1016/j.pmu.2014.02.004

Kazutoyo Inanaga MD, PhD

引用次数: 13

Improvement of refractory schizophrenia on using Amyloban®3399 extracted from Hericium erinaceum 猴头菌提取物Amyloban®3399对难治性精神分裂症的改善作用

Personalized Medicine Universe

Pub Date : 2014-07-01 DOI: 10.1016/j.pmu.2014.04.002

Kazutoyo Inanaga , Taketoshi Matsuki , Yoshio Hoaki , Koji Miki , Akira Shigemoto , Susumu Hirota , Nobuhiro Mori , Nobuyuki Hattori

引用次数: 4

Improvement of refractory schizophrenia on using Amyloban®3399 extracted from Hericium erinaceum 猴头菌提取物Amyloban®3399对难治性精神分裂症的改善作用

Personalized Medicine Universe

Pub Date : 2014-07-01 DOI: 10.1016/J.PMU.2014.04.002

K. Inanaga, Taketoshi Matsuki, Y. Hoaki, K. Miki, A. Shigemoto, Susumu Hirota, N. Mori, N. Hattori

引用次数: 4

Serum concentrations of diterpenoid alkaloids after oral administration of powdered processed aconite root 口服炮制附子粉末后血清二萜生物碱浓度的变化

Personalized Medicine Universe

Pub Date : 2014-07-01 DOI: 10.1016/j.pmu.2014.04.001

Hajime Nakae , Yuji Fujita , Shigeatsu Endo

引用次数: 1

Emerging histopathological prognostic biomarkers in hepatocellular carcinomas 新出现的肝细胞癌组织病理学预后生物标志物

Personalized Medicine Universe

Pub Date : 2014-07-01 DOI: 10.1016/J.PMU.2014.03.006

K. Yorita, Akinobu Ohno, H. Kataoka

引用次数: 1

Role of mitochondrial DNA changes in prostate cancer progression 线粒体DNA变化在前列腺癌进展中的作用

Personalized Medicine Universe

Pub Date : 2014-07-01 DOI: 10.1016/J.PMU.2014.03.005

M. Higuchi, A. Kim, C. C. Cook, Sara E. Prior, A. Gotoh

引用次数: 0

Syncope 晕厥

Personalized Medicine Universe

Pub Date : 2014-07-01 DOI: 10.1016/j.pmu.2014.02.001

Howard J. Kline

Purpose

Syncope is a common clinical problem characterized by a transient, spontaneously self-terminating loss of consciousness with complete and prompt recovery, the cause of which is insufficiency of cerebral blood flow creating generalized anoxia, most commonly due to a transient fall of systemic arterial pressure to levels below those tolerated by the cerebrovascular autoregulation mechanism. A thorough evaluation of the underlying cause of syncope is warranted in all patients to precisely diagnose the underlying mechanism or cause in order to provide the appropriate treatment of syncope since it is challenging for many reasons. The purpose of this review on syncope is to provide a thorough differential diagnosis as to the underlying cardiac and non-cardiac causes with methods of assessment of the specific causes. Knowledge of the specific cause, especially in the setting of structural heart disease or primary electrical cardiac disease, has an increased incidence of sudden death and overall mortality. It is also important to establish whether or not syncope is due to orthostatic hypotension since it is associated with a twofold increased mortality, whereas those individuals with neurally mediated syncope have an excellent prognosis.

晕厥是一种常见的临床问题，其特征是短暂的、自发的、自我终止的意识丧失，并迅速完全恢复，其原因是脑血流量不足造成全身性缺氧，最常见的原因是全身动脉压短暂下降到脑血管自动调节机制所能耐受的水平以下。全面评估晕厥的根本原因是必要的，在所有患者准确诊断的根本机制或原因，以提供适当的治疗晕厥，因为它是具有挑战性的许多原因。本综述的目的是提供一个彻底的鉴别诊断，作为潜在的心脏和非心脏原因的具体原因的评估方法。对具体原因的了解，特别是在结构性心脏病或原发性电性心脏病的情况下，会增加猝死的发生率和总死亡率。确定晕厥是否由直立性低血压引起也很重要，因为它与死亡率增加两倍有关，而神经介导的晕厥患者预后良好。

{"title":"Syncope","authors":"Howard J. Kline","doi":"10.1016/j.pmu.2014.02.001","DOIUrl":"https://doi.org/10.1016/j.pmu.2014.02.001","url":null,"abstract":"<div><h3>Purpose</h3><p><span>Syncope is a common clinical problem characterized by a transient, spontaneously self-terminating loss of consciousness with complete and prompt recovery, the cause of which is insufficiency of cerebral blood flow creating generalized anoxia, most commonly due to a transient fall of </span>systemic arterial pressure<span> to levels below those tolerated by the cerebrovascular autoregulation<span><span> mechanism. A thorough evaluation of the underlying cause of syncope is warranted in all patients to precisely diagnose the underlying mechanism or cause in order to provide the appropriate treatment of syncope since it is challenging for many reasons. The purpose of this review on syncope is to provide a thorough differential diagnosis as to the underlying cardiac and non-cardiac causes with methods of assessment of the specific causes. Knowledge of the specific cause, especially in the setting of structural heart disease or primary electrical cardiac disease, has an increased incidence of sudden death and overall mortality. It is also important to establish whether or not syncope is due to </span>orthostatic hypotension<span> since it is associated with a twofold increased mortality, whereas those individuals with neurally mediated syncope have an excellent prognosis.</span></span></span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"3 ","pages":"Pages 4-10"},"PeriodicalIF":0.0,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2014.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90131468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Personalized Medicine Universe

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀